GlassScriptPhysician profile
Nhi P Le
NPI 1003808163
$3,764.59
in general payments reported to CMS, 2019-2025
33 companies · $169 in 2025
The $169 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $856 · 2020: $510 · 2021: $720 · 2022: $658 · 2023: $418 · 2024: $433 · 2025: $169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,019.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,019.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $1,292.61 | 2019-2022 | |
| Lilly USA, LLC | $324.73 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $254.35 | 2021-2025 | |
| Horizon Therapeutics Plc | $237.37 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $164.24 | 2019-2023 | Trintellix |
| Pfizer INC. | $162.13 | 2019-2022 | |
| Allergan, INC. | $151.90 | 2020-2022 | |
| Amgen INC. | $149.95 | 2021-2023 | Otezla, Repatha |
| Regeneron Healthcare Solutions, INC. | $118.47 | 2024 | Dupixent |
| Axsome Therapeutics, INC. | $115.60 | 2024 | Auvelity |
| Galderma Laboratories, L.P. | $91.53 | 2019-2024 | |
| Exact Sciences Corporation | $83.61 | 2023-2024 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $71.04 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $58.26 | 2020-2021 | |
| Shire North American Group INC | $54.88 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $52.17 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $37.06 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $36.52 | 2025 | Sotyktu |
| Esperion Therapeutics, INC. | $33.79 | 2020-2021 | |
| Sebela Pharmaceuticals INC. | $29.70 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $28.48 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.46 | 2019-2021 | |
| Celgene Corporation | $24.13 | 2019 | |
| Ucb, INC. | $21.85 | 2023 | Cimzia |
| Almirall LLC | $19.96 | 2023 | Klisyri |
| Idorsia Pharmaceuticals US INC | $19.53 | 2023 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $18.45 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.46 | 2022 | |
| Janssen Biotech, INC. | $16.59 | 2019 | |
| Genzyme Corporation | $13.83 | 2024 | |
| Astellas Pharma US INC | $12.62 | 2019 | |
| Journey Medical Corporation | $12.28 | 2020 | |
| Currax Pharmaceuticals LLC | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nhi Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.